TDI Podcast: Dr. Kevin Doxzen on CRISPR (#573)

Dr. Kevin Doxzen provides deep knowledge into the cutting edge biotech area of CRISPR. We focus on the potential, morality and opportunities.

In this episode, we find out why ignorance is no longer bliss. Confirmation bias has been elevated with the fake-news brainwashing that has been firmly seeded. Specifically, the clear signals that were provided by Facebook and Twitter management over the past months and how it was ignored to the peril of investors.

Dr. Kevin Doxzen is the Science Communications Specialist at the Innovative Genomics Institute (IGI). The IGI is an academic research partnership between UC Berkeley and UC San Francisco that aims to develop and deploy DNA engineering technologies to solve real-world problems.

Kevin received a B.A. in Biophysics from Johns Hopkins University and went on to receive a Ph.D. in Biophysics from UC Berkeley in the lab of Dr. Jennifer Doudna. In his current position, Kevin aims to educate and empower the wider public to help understand the latest biotechnological advancements in genome editing and beyond.


TDI Managed Growth Strategy Virtual Tour

Craft Your Portfolio HERE

Want More Info?

  • This field is for validation purposes and should be left unchanged.

Stocks mentioned in this episode: (EDIT), (CRSP), (TWTR), (FB), (TSLA)